Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A, Pirrie SJ, Linton K, Warbey V, Paterson K, Davies AJ, Collins GP, Menne T, McKay P, Fields PA, Miall FM, Nagy E, Wheatley K, Reed R, Baricevic-Jones I, Barrington S, Radford J. Gibb A, et al. Among authors: fields pa. Br J Haematol. 2021 Apr;193(1):63-71. doi: 10.1111/bjh.17073. Epub 2020 Sep 14. Br J Haematol. 2021. PMID: 32926420 Free article. Clinical Trial.
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: fields p. Br J Haematol. 2019 Oct;187(2):185-194. doi: 10.1111/bjh.16070. Epub 2019 Jun 20. Br J Haematol. 2019. PMID: 31222719 Free article.
Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.
Hounsome L, Eyre TA, Ireland R, Hodson A, Walewska R, Ardeshna K, Chaganti S, McKay P, Davies A, Fox CP, Kalakonda N, Fields PA. Hounsome L, et al. Among authors: fields pa. Br J Cancer. 2022 Jan;126(1):134-143. doi: 10.1038/s41416-021-01525-4. Epub 2021 Oct 5. Br J Cancer. 2022. PMID: 34611308 Free PMC article.
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields PA, Gunawan A, Oliver R, Booth S, McMillan A, Fox CP, Bishton M, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: fields pa. Br J Haematol. 2019 Aug;186(4):e94-e98. doi: 10.1111/bjh.15927. Epub 2019 Apr 24. Br J Haematol. 2019. PMID: 31020646 Free article. No abstract available.
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.
Booth S, Plaschkes H, Kirkwood AA, Gibb A, Horgan P, Higham C, Oladipo JM, Browning J, Khan U, Tseu B, Chen L, Willan J, Wolf J, Gunawan A, Fields P, Ebsworth T, Lown R, Gordon-Walker D, Shah N, Linton KM, Collins GP, Kothari J, Hildyard C, Eyre TA. Booth S, et al. Among authors: fields p. Blood Adv. 2020 Sep 22;4(18):4337-4346. doi: 10.1182/bloodadvances.2020002553. Blood Adv. 2020. PMID: 32915975 Free PMC article.
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Eyre TA, Wilson W, Kirkwood AA, Wolf J, Hildyard C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Kothari J, Fox CP, Martinez-Calle N, McMillan A, Bishton M, Collins GP, Hatton CSR. Eyre TA, et al. Among authors: fields p. Blood Adv. 2021 Apr 27;5(8):2229-2236. doi: 10.1182/bloodadvances.2021004286. Blood Adv. 2021. PMID: 33890978 Free PMC article.
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, Radford J, Menne T, Karnad A, Zain JM, Fields P, Havenith K, Cruz HG, He S, Boni J, Feingold J, Wuerthner J, Horwitz S. Hamadani M, et al. Among authors: fields p. Lancet Haematol. 2021 Jun;8(6):e433-e445. doi: 10.1016/S2352-3026(21)00103-4. Lancet Haematol. 2021. PMID: 34048682 Free PMC article. Clinical Trial.
453 results